Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 58 of 58 matching drugs for PTK6 — including drugs targeting any of its 20 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
atezolizumab, tivozanib PTK6 Direct 1
sirolimus, vandetanib PTK6 Direct 1
tivozanib PTK6 Direct 1
vandetanib PTK6 Direct yes 1
vandetanib, 5 fluorouracil (fu), carboplatin, paclitaxel, external beam radiation therapy (rt) PTK6 Direct 1
vandetanib, adjuvant therapy PTK6 Direct 1
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib ALK SSL via ALK 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib LCK SSL via LCK 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SRC SSL via SRC 3
crizotinib ALK SSL via ALK yes 3
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel ALK SSL via ALK 2
alectinib, stereotactic radiosurgery ALK SSL via ALK 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment LCK SSL via LCK 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment SRC SSL via SRC 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib ALK SSL via ALK 2
nintedanib LCK SSL via LCK 2
nintedanib SRC SSL via SRC 2
nintedanib, pembrolizumab LCK SSL via LCK 2
nintedanib, pembrolizumab SRC SSL via SRC 2
afatinib, dasatinib, palbociclib, everolimus, olaparib LCK SSL via LCK 1
afatinib, dasatinib, palbociclib, everolimus, olaparib SRC SSL via SRC 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib ALK SSL via ALK 1
bevacizumab, dasatinib, placebo LCK SSL via LCK 1
bevacizumab, dasatinib, placebo SRC SSL via SRC 1
biopsy, biospecimen collection, crizotinib, radiologic examination ALK SSL via ALK 1
bosutinib SRC SSL via SRC yes 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab LCK SSL via LCK 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab SRC SSL via SRC 1
ceritinib, cisplatin, gemcitabine hydrochloride, laboratory biomarker analysis, paclitaxel albumin-stabilized nanoparticle formulation, pharmacological study ALK SSL via ALK 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride LCK SSL via LCK 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride SRC SSL via SRC 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method LCK SSL via LCK 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method SRC SSL via SRC 1
dasatinib, laboratory biomarker analysis, physiologic testing LCK SSL via LCK 1
dasatinib, laboratory biomarker analysis, physiologic testing SRC SSL via SRC 1
dasatinib, mfolfox6 LCK SSL via LCK 1
dasatinib, mfolfox6 SRC SSL via SRC 1
dasatinib, pharmacological study LCK SSL via LCK 1
dasatinib, pharmacological study SRC SSL via SRC 1
dasatinib, temozolomide, placebo, radiation therapy LCK SSL via LCK 1
dasatinib, temozolomide, placebo, radiation therapy SRC SSL via SRC 1
disulfiram, copper, alkylating agents GPI SSL via GPI 1
lorlatinib, lorlatinib with chemotherapy1, lorlatinib with chemotherapy 2, lorlatinib post radiation ALK SSL via ALK 1
ponatinib LCK SSL via LCK 1
ponatinib SRC SSL via SRC 1
alectinib ALK SSL via ALK yes 0
alectinib hydrochloride ALK SSL via ALK yes 0
brigatinib ALK SSL via ALK yes 0
ceritinib ALK SSL via ALK yes 0
dasatinib LCK SSL via LCK yes 0
dasatinib SRC SSL via SRC yes 0
entrectinib ALK SSL via ALK yes 0
lorlatinib ALK SSL via ALK yes 0
pazopanib LCK SSL via LCK yes 0
pazopanib hydrochloride LCK SSL via LCK yes 0
tirbanibulin SRC SSL via SRC yes 0
vandetanib LCK SSL via LCK yes 0
vandetanib SRC SSL via SRC yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.